KALRAY
19.10.2020 18:02:14 CEST | Business Wire | Press release
Kalray (Paris:ALKAL) (Euronext Growth Paris: FR0010722819 – ALKAL), a pioneer in processors for new intelligent systems, today announced that its K200™ Coolidge™ based smart storage adapter solution has been certified for NVM ExpressTM over Fabrics (NVMe-oF) with TCP (NVMe™/TCP) protocol by the NVM Express organization through the University of New Hampshire InterOperability Laboratory (UNH-IOL), an independent testing provider of standard conformance solutions and multi-vendor interoperability.
Data Centers are undergoing a very important revolution with rapidly evolving network architectures and technologies. This is mainly due to the explosion of usages, the surge of data to be processed and the resulting exponential growth of the number of machines to be managed to support this growth.
Until now, storage has been one major bottleneck of this expansion. The introduction of flash memory-based SDD (Solid-State Drive) with hyper-fast communication protocols such as NVMe™/TCP, offers a breakthrough solutions to the industry to massively scale up and increase performance of existing data centers. Smart storage adapters and associated storage appliances (including Ethernet storage expansion servers called “JBOF”) are at the heart of this revolution.
Dennis Hahn , Senior Analyst, Cloud & Data Center at OMDIA stated in his report, Data Center Storage Equipment Market Tracker: “NVMe-oF JBOF is just starting to experience an uptake in on-premises enterprise DC segments for its ultra-high performance and is ramping aggressively for use by hyper converged infrastructure and in data intensive applications ”.
Eric Baissus , President and CEO of Kalray, has declared: “Certification is a major step in our journey to mass production. Kalray is on schedule with its strategic roadmap and actively preparing the commercial deployment of a new type of hyper-fast storage solution. Together with our partners and customers, we are actively working to integrate and qualify our technology and products ”.
Based on its 3rd generation MPPA® (Massively Parallel Processor Array) processor, Kalray’s storage smart adapter solution, targets the new generations of hyper-fast storage solutions. Whereas competitive solutions are limited in term of performance, for example when demanding algorithms such as data protection and footprint reduction are running, Coolidge™ Intelligent processors have the capability to run such protocols without degradation of the server bandwidth, in real time. Kalray’s fully programmable smart storage adapter delivers high performance while ensuring offloading of demanding data services. This Coolidge™-based solution also offers new horizons in term of storage performance, targeting the booming market of data intensive application such as AI, Data Analytics or IoT.
Kalray's solution offers both extremely high computing power capable of processing considerable data volumes while minimizing energy consumption; as well as on-the-fly heterogenous processing capabilities. The K200™ smart storage adapter is a standard PCIe card supporting both NVMe™/TCP and NVMe™/RoCE, with associated software suite, highly configurable for composability needs, based on its MPPA® processor implementing leading edge interfaces, including PCIe Gen4 x16 and 2 x 100G Ethernet. As an example, coupled with the latest PCIe Gen4 AMD processor MPPA® can be used as an accelerator delivering a full duplex bandwidth of up to 200 Gbit/s. In addition, K200™ delivers up to 4 MIOPS (Millions of I/O Operations Per Second).
For more information, please contact Kalray’s sales team at contact@kalrayinc.com
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, pioneer in a new generation of processors for intelligent systems. MPPA® Intelligent processors are able to capture and analyze on the fly massive data flows, close to where they are generated, and interact in real time with the outside world. These processors are capable of running demanding AI algorithms and simultaneously a wide set of different processing and control tasks such as mathematical algorithms, signal processing, network or storage software stacks. Kalray’s Intelligent Processors can be deployed in fast-growing sectors of Edge Computing and AI: Modern data centers, networks (5G), autonomous vehicles, healthcare equipment, industry 4.0, drones and robots… Kalray’s offering includes processors, system boards and a software suite, for a broad spectrum of customers such as data storage systems and compute server manufacturers, intelligent system integrators and consumer product manufacturers such as car makers. Founded in 2008 as a spin-off of CEA French lab, Kalray counts among its investors: Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance. Read more at: www.kalrayinc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005593/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom